This $773,359 Project Grant award from the National Institutes of Health (NIH) under the Family Smoking Prevention and Tobacco Control Act Regulatory Research program (CFDA 93.077) will fund a randomized controlled trial to examine the potential public health impact of nicotine pouches as a cigarette substitute. The study will enroll 284 adult daily smokers who are not planning to quit and randomly assign them to receive either 3-mg nicotine pouches, 6-mg nicotine pouches, nicotine...
This Project Grant award from the National Institutes of Health's Family Smoking Prevention and Tobacco Control Act Regulatory Research program (CFDA 93.077) provides $1,197,896 to the University of Oklahoma Health Sciences Center to conduct a longitudinal study examining the impact of electronic nicotine delivery system (ENDS) product characteristics on use behaviors and abuse liability among young adults aged 18-25. The research aims to use a novel measurement approach combining traditional...
This Project Grant award of $622,957 from the National Institutes of Health (NIH) Office of the Director under the Family Smoking Prevention and Tobacco Control Act Regulatory Research program (CFDA 93.077) will fund research by Duke University to investigate the impact of novel tobacco product designs and synthetic additives on use initiation and preference behavior. The key objectives of the research are to: 1) analyze the chemical composition of oral nicotine pouches and...
The federal Project Grant award R01CA289551 for $661,139, provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program, supports a 6-month randomized clinical trial to evaluate the effectiveness of oral nicotine pouches (ONPs) versus nicotine replacement therapy (NRT) in reducing smoking among adult smokers in rural Appalachian counties. The study, conducted by The Ohio State University, aims to determine whether ONPs are suitable...
The National Institute on Drug Abuse (NIDA) awarded Duke University a $241,500 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to study the impact of very low nicotine content (VLNC) cigarettes on smoking cessation outcomes among individuals with opioid use disorder and chronic pain. The research aims to examine how switching to VLNC cigarettes affects the bidirectional relationship between smoking, pain, and timing of buprenorphine administration, as well as...
The federal Project Grant award R01DA060187, funded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to examine the effects of maternal exposure to electronic nicotine delivery system (ENDS) aerosols during pregnancy on addiction-related behaviors and neurobiology in offspring. The $1,315,596 award to the Hennepin Healthcare Research Institute will support a 5-year research initiative to evaluate measures of impulsivity,...
This Project Grant awarded by the National Institutes of Health (NIH) Office of the Director under the Family Smoking Prevention and Tobacco Control Act Regulatory Research program (CFDA 93.077) provides $1,176,627 to Yale University to develop and test improved labeling for nicotine in electronic nicotine delivery systems (ENDS). The project aims to create two new label designs: 1) a revised nicotine concentration label that better conveys nicotine strength compared to current FDA-required...
The National Institutes of Health (NIH), through the Family Smoking Prevention and Tobacco Control Act Regulatory Research program (CFDA 93.077), awarded a $669,321 project grant to the Regents of the University of California at Riverside (UC Riverside). The grant supports a 1-year study to characterize new and emerging ingredients, acids, toxicants, and indicators of non-tobacco nicotine in electronic cigarette (e-cigarette) products. The research will involve: Analyzing 600 commercial...
This Project Grant award of $1,951,307.00, made by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund a study investigating the patterns and trajectories of dual use of combustible and electronic cigarettes. The study, led by the Medical University of South Carolina (MUSC) in collaboration with the University of Vermont and the University of New Mexico, will assess the natural use histories of dual users, exclusive smokers, and...
This $370,000 Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Family Smoking Prevention and Tobacco Control Act Regulatory Research program (CFDA 93.077) supports research to determine the impact of synthetic coolants on nicotine's abuse liability and initiation-related vaping behaviors. The grant recipient, Marshall University Research Corporation (MURC), will utilize a novel e-vape nicotine self-administration assay in mice to examine how...
EFFECT OF PRODUCT CHARACTERISTICS ON THE ABUSE LIABILITY OF NICOTINE POUCHES - PROJECT SUMMARY THERE IS A GROWING SECTOR OF MODERN TOBACCO-FREE ORAL NICOTINE POUCHES (NPS) THAT ARE FEDERALLY REGULATED AS NON-MEDICINAL NICOTINE/TOBACCO PRODUCTS. WHILE NPS EMPLOY MARKETING APPROACHES THAT MAY ATTRACT CURRENT TOBACCO USERS, SUCH AS MARKETING THEMES CONNOTING MINIMAL HARM, INFORMATION ON THE LONG-TERM HEALTH EFFECTS OF NPS IS LACKING. NPS MAY APPEAL TO YOUNG ADULTS BECAUSE THEY ARE AVAILABLE IN SIMILAR PRODUCT CHARACTERISTICS (E.G., NICOTINE CONCENTRATION, PROTONATED NICOTINE) THAT MANY YOUNG PEOPLE PREFER TO USE IN E-CIGARETTES. IN ADDITION, NPS MAY BE OF PARTICULAR INTEREST TO YOUNG ADULT E-CIGARETTE USERS BECAUSE THESE PRODUCTS CAN BE USED DISCREETLY WHERE VAPING IS NOT ALLOWED, WHICH MAY TRANSLATE INTO AN INCREASED LIKELIHOOD OF BECOMING DUAL USERS OF E-CIGARETTES AND NPS. INDEED, APPROXIMATELY 15% YOUNG ADULTS WHO USED EC IN THE PAST 30 DAYS WERE PAST 30-DAY NP USERS. MANUFACTURERS OF MODERN NPS USE ACID ADDITIVES TO LOWER PH, WHICH CHANGES NICOTINE FROM A FREE-BASE TO A PROTONATED NICOTINE, RESULTING IN IMPROVED APPEAL AND SENSORY EXPERIENCE AND HIGHER ABUSE LIABILITY. THUS, NICOTINE CONCENTRATION AND PH IN MODERN NPS SHOULD BE FOCAL TARGETS FOR REGULATORY POLICIES. EVIDENCE IS ALSO LACKING ON MECHANISMS MEDIATING DIFFERENCES IN PRODUCT APPEAL AND ABUSE LIABILITY OF NPS ACROSS PRODUCTS VARYING IN NICOTINE CONCENTRATION AND PH LEVEL. THE SCIENTIFIC OBJECTIVE OF THIS RESEARCH PLAN IS TO ASSESS THE EFFECT OF VARIATION IN NICOTINE CONCENTRATION IN NPS AND ITS INTERACTION EFFECT WITH PH LEVEL ON THREE PROXIMAL OUTCOMES OF RELEVANCE TO FDA REGULATION: (1) SENSORY ATTRIBUTES, (2) PRODUCT APPEAL, AND (3) ABUSE LIABILITY AMONG YOUNG ADULT DUAL USERS OF NPS AND E-CIGARETTES. THIS INNOVATIVE PROJECT PROPOSES TO CONDUCT DOUBLE-BLIND WITHIN-SUBJECT RANDOMIZED CLINICAL TRIALS IN WHICH PARTICIPANTS (N156 [AIM 1 N = 72; AIM 2 N = 84]) WILL ADMINISTER NPS VARIED BY NICOTINE CONCENTRATION (E.G., 4 VS 2 MG) AND PH (E.G., 9 VS 8, 1 POINT DIFFERENCE) ACROSS TWO FLAVORS (E.G., MINT, FRUIT) TO ACHIEVE THE PROJECT AIMS: TO EVALUATE THE EFFECTS OF NICOTINE CONCENTRATION, PH, AND FLAVOR ON SUBJECTIVE PRODUCT APPEAL AND SENSORY ATTRIBUTES OF NPS (AIM 1); TO ASSESS THE EFFECTS OF NICOTINE CONCENTRATION AND ITS INTERPLAY WITH PH ON ABUSE LIABILITY OF NPS (AIM 2); TO ESTIMATE THE EXTENT TO WHICH SENSORY ATTRIBUTE MEDIATES THE PH-MODERATED EFFECT OF NICOTINE CONCENTRATION ON PRODUCT APPEAL AND ABUSE LIABILITY (AIM 3). THE FINDINGS OF THIS PROPOSED RESEARCH WILL PROVIDE THE FDA WITH NEW EVIDENCE NECESSARY TO INFORM REGULATORY RESTRICTIONS ON PRODUCT CHARACTERISTICS AND CONSTITUENTS OF NPS, WHICH MAY PUT YOUNG ADULTS AT RISK OF USING A NOVEL CLASS OF ORAL NICOTINE PRODUCTS. A CAREER DEVELOPMENT PLAN THAT COMPLEMENTS THE RESEARCH PLAN BUILDS ON THE APPLICANT'S BACKGROUND IN BEHAVIORAL EPIDEMIOLOGY AND QUANTITATIVE ANALYTIC SKILLS, WHICH OUTLINES NEW TRAINING IN THREE AREAS: (1) CLINICAL TRIAL EXPERIMENTS TESTING THE EFFECTS OF EXPOSURE TO TOBACCO PRODUCTS ON BEHAVIORAL RESPONSES (E.G., ABUSE LIABILITY), (2) PRODUCT CHARACTERISTICS AND CONSTITUENTS OF EMERGING ORAL NICOTINE PRODUCTS, AND (3) WITHIN-SUBJECT DATA AND CAUSAL MEDIATION ANALYSES. THE COMBINED RESEARCH AND TRAINING PLAN WILL PREPARE THE CANDIDATE AS AN INDEPENDENT INVESTIGATOR WITH EXPERTISE IN TOBACCO REGULATORY SCIENCE.